We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Medtronic (MDT - Free Report) closed the most recent trading day at $88.90, moving +0.05% from the previous trading session. This change outpaced the S&P 500's 0.94% loss on the day. At the same time, the Dow lost 0.87%, and the tech-heavy Nasdaq lost 1.18%.
Heading into today, shares of the medical device company had gained 5.41% over the past month, lagging the Medical sector's gain of 6.01% and the S&P 500's gain of 8.01% in that time.
Wall Street will be looking for positivity from MDT as it approaches its next earnings report date. This is expected to be February 19, 2019. In that report, analysts expect MDT to post earnings of $1.24 per share. This would mark year-over-year growth of 5.98%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.55 billion, up 2.46% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.13 per share and revenue of $30.53 billion. These totals would mark changes of +7.55% and +1.93%, respectively, from last year.
Any recent changes to analyst estimates for MDT should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.08% lower. MDT is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, MDT is holding a Forward P/E ratio of 17.34. This valuation marks a discount compared to its industry's average Forward P/E of 23.4.
Also, we should mention that MDT has a PEG ratio of 2.36. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Products industry currently had an average PEG ratio of 2.26 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MDT in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medtronic (MDT) Gains As Market Dips: What You Should Know
Medtronic (MDT - Free Report) closed the most recent trading day at $88.90, moving +0.05% from the previous trading session. This change outpaced the S&P 500's 0.94% loss on the day. At the same time, the Dow lost 0.87%, and the tech-heavy Nasdaq lost 1.18%.
Heading into today, shares of the medical device company had gained 5.41% over the past month, lagging the Medical sector's gain of 6.01% and the S&P 500's gain of 8.01% in that time.
Wall Street will be looking for positivity from MDT as it approaches its next earnings report date. This is expected to be February 19, 2019. In that report, analysts expect MDT to post earnings of $1.24 per share. This would mark year-over-year growth of 5.98%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.55 billion, up 2.46% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.13 per share and revenue of $30.53 billion. These totals would mark changes of +7.55% and +1.93%, respectively, from last year.
Any recent changes to analyst estimates for MDT should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.08% lower. MDT is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, MDT is holding a Forward P/E ratio of 17.34. This valuation marks a discount compared to its industry's average Forward P/E of 23.4.
Also, we should mention that MDT has a PEG ratio of 2.36. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Products industry currently had an average PEG ratio of 2.26 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MDT in the coming trading sessions, be sure to utilize Zacks.com.